Core Viewpoint - Sharps Technology, Inc. is urging shareholders to vote in favor of a reverse stock split proposal to maintain compliance with NASDAQ's minimum bid price requirement and avoid delisting [2][3][4]. Company Overview - Sharps Technology, Inc. is a medical device and pharmaceutical packaging company that specializes in patented syringe products designed for safety and low waste [10]. - The company has a manufacturing facility in Hungary and is collaborating with Nephron Pharmaceuticals to enhance its manufacturing capacity in the U.S. [10]. Reverse Stock Split Proposal - The company is requesting approval for a reverse stock split in the range of 1-for-8 to 1-for-22 to ensure compliance with NASDAQ's minimum price requirement of $1.00 per share [2][3][8]. - A previous approval for a 1-for-8 reverse stock split was granted at a special shareholder meeting on July 15, 2024, but has not yet been implemented [2][3]. - The reverse stock split is expected to help maintain trading volume and attract a broader range of investors, which could facilitate capital access for growth strategies [5][6]. Shareholder Voting - The special shareholder meeting is scheduled for October 7, 2024, and shareholders are encouraged to vote their proxies beforehand [7][9]. - The Board of Directors unanimously supports the reverse stock split proposal and urges all shareholders to vote "FOR" it [7][9].

Core Points - Sharps Technology, Inc. has successfully closed a secured bridge loan financing of approximately $3.5 million [1][2] - The financing involved the sale of securities, where investors received $1,250 in secured notes and shares of common stock for every $1,000 invested, totaling $4,375,000 in principal amount of notes and 5,700,006 shares of common stock [2] - The net proceeds from the offering will be used for general corporate purposes and working capital [2] Company Overview - Sharps Technology is a medical device and pharmaceutical packaging company that specializes in patented smart-safety syringe products [6] - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [6] - Sharps Technology has a manufacturing facility in Hungary and is collaborating with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. [6]

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the "Company"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the "Bridge Financing") of approximately $3.5 million. The Bridge Financing consisted of the sale of approximately $3.5 million in securities, with purchasers agreein ...

Definitive agreement sells out the 10mL SoloGard production capacity at Sharps' manufacturing site in the EU and drives expansion to support the project's growth in the future Sharps' portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter NEW YORK, July 25, 202 ...

Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company's continued growth. NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Executive Officer. Dear Fellow Shareholders: Up for vote on the ballot are the following three p ...

Voting deadline is Friday, July 12, at 11:59 p.m. Eastern Time. In order to continue Sharps Technology's solid progress toward achieving its goals, I want to share with you the importance of the three proposals on the shareholder ballot and ask you to take a few moments to vote to approve them. Our leadership team is moving forward aggressively to increase the Company's valuation through strategic partnerships and customer opportunities that will drive the need to expand our manufacturing capacity in Europe ...

"This shipment is a great step in building strategic partnerships within the entire Latin American distribution network and supporting region-wide efforts to improve medical safety and healthcare outcomes," comments Robert Hayes, Sharps Technology CEO. "While implementing wide-scale change can be challenging, based on our studies we are confident that once healthcare practitioners use Securegard syringes, they will want to continue to use them, leading to long-term purchase orders and deliveries." NEW YORK, ...

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, has made the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders were placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant ...

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-inclass syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET. Additionally, a five-year, $200 million sales agreement with Nephron will see Sharps' next-generation copolymer prefillable syringes manufactured at the South Carolina plant and 10mL SoloGard polypropylene syringes fro ...

Signed PO secures first 12 months of syringe product orders against Sharps and Nephron's five-year, $200 million Syringe Sales Agreement. Braden Miller, Sharps Director of Product Development, commented, "Sharps has developed an exciting alternative to glass syringes through the use of molded inert polymers, offering a high-quality solution compared to traditional glass syringe systems." Sharps prefillable polymer syringes have many of the same characteristics as traditional glass designs to support long te ...